A Phase Ib/II trial of daratumumab in combination with nivolumab in patiens with relapsed or refractory multiple myeloma

Trial Profile

A Phase Ib/II trial of daratumumab in combination with nivolumab in patiens with relapsed or refractory multiple myeloma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Daratumumab (Primary) ; Nivolumab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Jan 2017 New trial record
    • 05 Jan 2017 According to a Janssen Biotech media release, this trial is expected to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top